<unk> , sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union. It is an inhibitor of vascular endothelial growth factor (VEGF).
Aflibercept
Vatalanib
Nintedanib
Ranibizumab
Angiozyme
Avelumab
Gilteritinib
Abrocitinib